FDA approved Merck’s hypoxia-inducible factor-2 alpha inhibitor WELIREG (belzutifan)
On Aug. 13, 2021, Merck announced that the U.S. Food and Drug Administration (FDA) had approved WELIREG, an…
von Hippel-Lindau
On Aug. 13, 2021, Merck announced that the U.S. Food and Drug Administration (FDA) had approved WELIREG, an…